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gust 2010); its position in the guideline is very prominent 
 [1] . The development of this new guideline must have 
started in close temporal relationship to dronedarone’s 
EU market approval in November 2009, given the usual 
time requirements for the completion of such work.
 The explicit positioning of the compound in the new 
guideline resulted in an increased rate of prescription. 
However, complaints by physicians and patients about 
side effects and a relatively low efficacy accumulated rap-
idly. In January 2011, a public letter (a ‘Dear Doctor let-
ter’) to all German physicians warned of serious hepato-
toxicity necessitating liver transplantation. On July 7, 
2011, the drug’s manufacturer reported that a large phase 
IIIb study (PALLAS) in patients with atrial fibrillation 
had to be prematurely stopped as dronedarone had caused 
a significant increase of cardiovascular events such as 
stroke or myocardial infarction versus placebo  [2] . The 
manufacturer pointed out that in PALLAS, patients with 
permanent atrial fibrillation were included, whereas in 
ATHENA, which was the pivotal trial leading to market 
approval, only patients with nonpermanent atrial fibril-
lation were included. In the interim, the full paper has 
 Medical guidelines are typically generated by medical 
associations to guide physicians through the jungle of 
biomedical knowledge, empirics and opinions. They are 
normative and, often, particularly in Europe, are regard-
ed as binding for physicians; thus, in law courts, they are 
highly influential documents. However, according to 
good medical practice, guidelines should not be applied 
without a critical assessment of the individual case. 
Though an existing guideline may seem easily applicable, 
doctors are under obligation to search for the special fea-
tures of the patient and to act accordingly which may sug-
gest a deviation from the guideline. Nonetheless, in daily 
practice guidelines often are regarded as if they were laws; 
during basic and advanced medical education adherence 
to guidelines is a major objective.
 What if specific guidelines do not reflect rigorous or 
complete scientific data, as is often the case? Many guide-
lines are putatively based on the ‘level of evidence C’, 
which is essentially the absence of strong evidence and, 
thus, are largely the product of the inferences and opin-
ions of the writers.
 This question was triggered once again by a recent 
event. The new antiarrhythmic drug, dronedarone, be-
came part of the new guidelines for the treatment of atri-
al fibrillation by the European Society of Cardiology (Au-
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been published  [3] and results seem even worse than 
those initially reported, including a significant doubling 
of mortality from any cause.
 It is obvious that guidelines have to reflect actual de-
velopments and novel data; however, here it appears that 
the guideline was hastily changed on the basis of a single 
study (ATHENA) before this compound was more exten-
sively tested. Yet it has to be acknowledged that ATHENA 
was the largest trial ever to scrutinize an antiarrhythmic 
drug in atrial fibrillation, and the immediate conclusions 
for the population studied were not revoked. Recently, 
French health authorities concluded that the efficiency of 
dronedarone was ‘insufficient’; this decision was pub-
lished before the news on PALLAS  [4] . It also reflects the 
opinions of expert critics on the design of ATHENA and 
the safety of the compound.
 The recent finalization of dronedarone’s assessment 
by the European Medicine Agency is completely in line 
with the negative judgment described above  [5] ; in con-
sequence, the manufacturer changed the labeling infor-
mation and restricted the use of dronedarone to cases for 
whom alternative means of treatment have failed (see the 
‘Dear Doctor Letter’, September 2011).
 This case is an excellent example of a premature guide-
line change which caused considerable discomfort in the 
medical community. Although other explanations are 
also likely to have been involved, the guideline decision 
could support the until-now unsubstantiated belief that 
key opinion leaders contributing to this change may have 
been biased, even if unintentionally.
 This is also not a solitary case: the platelet inhibitor 
ticagrelor was included in the new European guidelines 
on myocardial revascularization before it was approved 
in the European Union  [6] . The guideline change and 
market approval were based on a single large trial, PLA-
TO. For this trial, however, an inconsistency regarding 
the geographical distribution of results has become 
known  [7] : in Poland and Hungary, significant superior-
ity over clopidogrel was observed, whereas ticagrelor was 
inferior to this compound in the US (despite this, it was 
recently approved by the FDA). The producer performed 
the monitoring of the study in Poland and Hungary, 
while in the US this was done by an independent CRO.
 This is another example of how in the context of our 
accelerated and hasty pace of incorporation of medical 
‘innovation’, guidelines may be changed before impor-
tant questions have been answered. It is obvious that phy-
sicians and patients become unsettled by such develop-
ments and that physicians are heavily burdened by the 
obligation to critically examine guidelines. This is par-
tially due to the fact that, in Europe, healthcare systems 
normally do not pay for more than 5- to 10-minute con-
tacts between physicians and patients. One of the coping 
strategies to respond to this time limitation is to employ 
guidelines as ‘cookbook recipes’ to speed evaluation and 
management.
 This dilemma does not allow for complacency: even if 
in the areas with ‘solid data’ major questions remain un-
answered, a very basic problem of the guideline concept 
has also to be acknowledged and properly dealt with. 
Doctors and lawyers tend to overestimate the normative 
value of guidelines; they should become more conscious 
about these limitations and should encourage careful 
evaluation of the applicability of the unmodified guide-
line to the individual patient. In addition, a delay of dura-
tion appropriate to the individual case in finalizing a 
guideline involving a new drug should be regularly con-
sidered if the database is generally acknowledged to be 
limited. The guideline should be more tentative and 
should encourage tailoring or even negating application 
to an individual patient when the physician’s judgment 
suggests that this is appropriate.
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